Abstract

The safety and clinical efficacy of superficial temporal artery-middle cerebral artery bypass grafting combined with superficial temporal artery branching and cerebral-dural-temporal vascular grafting in the treatment of adult moyamoya disease are investigated. A retrospective analysis of the data of 22 adult patients with moyamoya disease who underwent superficial temporal artery-brain artery bypass grafting combined with superficial temporal artery branching and cerebral-dural-muscle vascular stenting from June 2012 to June 2018 is performed to analyze the patient’s treatment outcome, functional recovery, and complications. Among the 22 patients, 17 (77.3 %) patients have improved clinical symptoms 1 w after surgery, and 5 patients (22.7 %) have no significant improvement in symptoms. After 3 mo follow-up, 21 patients (95.5 %) have significant improvement in clinical symptoms and spontaneous living ability compared with preoperative, and 1 patient (5.3 %) has no improvement in symptoms of new cerebral infarction. In patients with ischemic moyamoya disease, the clinical symptoms and quality of life of patients with superficial temporal artery-middle cerebral artery bypass graft combined with superficial temporal artery branching and cerebral-dural-temporal muscle vascularization are significantly improved. It shows that it can improve the prognosis of patients with ischemic moyamoya disease and has important clinical significance for the recovery of neurological function and the improvement of quality of life.